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Evidence suggests vitamin D has preventive potential in asthma; however, not all children benefit 
from this intervention. This study aimed to investigate whether variation in the functional 17q21 
single nucleotide polymorphism rs12936231 affects the preventive potential of vitamin D against 
asthma.
A combined secondary analysis of two randomised controlled trials of prenatal vitamin D 
supplementation for the prevention of asthma in offspring (Vitamin D Antenatal Asthma 
Reduction Trial (VDAART) and Copenhagen Prospective Studies on Asthma in Childhood 2010 
(COPSAC2010)) was performed, stratifying by genotype and integrating metabolite data to explore 
underlying mechanisms.
The protective effect of vitamin D on asthma/wheeze was evident among children with the low-
risk rs12936231 GG genotype (hazard ratio (HR) 0.49, 95% CI 0.26–0.94, p=0.032) but not the 
high-risk CC genotype (HR 1.08, 95% CI 0.69–1.69, p=0.751). In VDAART, in the GG genotype 
vitamin D supplementation was associated with increased plasma levels of sphingolipids, 
including sphingosine-1-phosphate (β 0.022, 95% CI 0.001–0.044, p=0.038), but this was not 
evident with the CC genotype, known to be associated with increased expression of ORMDL3 in 
bronchial epithelial cells. Sphingolipid levels were associated with decreased risk of asthma/
wheeze, and there was evidence of interactions between sphingolipid levels, vitamin D and 
genotype (p-interactionvitaminD*genotype*sphingosine-1-phosphate=0.035). In a cellular model, there was 
a significant difference in the induction of sphingosine-1-phosphate by vitamin D between a 
control human bronchial epithelial cell line and a cell line overexpressing ORMDL3 (p=0.002).
Results suggest prenatal vitamin D supplementation may reduce the risk of early childhood 
asthma/wheeze via alterations of sphingolipid metabolism dependent on the 17q21 genotype.
Introduction
Asthma is hypothesised to emerge from gene–environment interactions disturbing fetal 
developmental processes in utero [1–3]. Therefore, novel preventive methods targeted at 
pregnant women may help alleviate the burden of asthma.
We recently conducted two independent randomised clinical trials (RCTs) of prenatal 
vitamin D supplementation for the reduction of asthma among offspring: the Vitamin D 
Antenatal Asthma Reduction Trial (VDAART) [4] and the Copenhagen Prospective Studies 
on Asthma in Childhood 2010 (COPSAC2010) [5]. A combined analysis of the two trials 
demonstrated a significant 25% reduction in risk [6]. However, not all children benefited 
from the intervention and we hypothesise that the child’s underlying genetic susceptibility to 
asthma may have attenuated the impact of vitamin D supplementation on asthma 
development.
Chromosomal region 17q21 is the most replicated childhood asthma locus [7, 8]. The high-
risk genotype defines an early-onset asthma phenotype with recurrent wheeze [9] that can be 
modulated by environmental exposures [1, 2, 10]. Expression of ORMDL3 at the 17q21 
locus is thought to confer an increased risk of asthma, in part through inhibition of the serine 
palmitoyltransferase (SPT) enzyme. SPT catalyses the first step in the synthesis of 
sphingolipids: the condensation of serine and palmitoyl coenzyme A to produce 3-
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ketodihydrosphingosine [11]. It is therefore a key regulator of sphingolipid levels, which 
have been associated with bronchial reactivity and asthma in mechanistic studies [12–14]. 
However, human studies investigating whether ORMDL3-regulated sphingolipid pathways 
contribute to the pathogenesis of asthma are lacking [15].
In this study, we explored the hypothesis that genetic variation in the functional single 
nucleotide polymorphism (SNP) rs12936231 affected the outcome of our prenatal vitamin D 
trials, through alterations of sphingolipid metabolism. We focused on this SNP in particular 
because it has been denoted as the strongest candidate for a functional SNP within 17q21 
[16], it is known to influence the expression of ORMDL3 in multiple cell types [16, 17], it 
has been repeatedly associated with asthma [12] and it has links to vitamin D in the 
literature [18]. We conducted this study in the VDAART and COPSAC2010 populations, 
utilising genotype data, sphingolipid metabolite levels and cell line studies.
Methods
Study populations
The study populations have been described in detail previously [19, 20] and the trial 
protocols [4–6] are registered with ClinicalTrials.gov as NCT00920621 (VDAART) and 
NCT00856947 (COPSAC2010). In brief, both studies recruited pregnant women (VDAART: 
10–18 weeks; COPSAC2010: 22–26 weeks) and randomised them to daily vitamin D3 
(VDAART: 4000 IU; COPSAC2010: 2400 IU) or placebo until delivery. All women 
additionally received a daily multivitamin containing 400 IU vitamin D3. Written and oral 
consent, including for secondary analyses, were obtained from both cohorts (full details in 
supplementary methods).
Data collection
In both cohorts, children were followed for incident asthma/recurrent wheeze (defined in 
supplementary methods) and genotyped for the 17q21 rs12936231 SNP with the Illumina 
Infinium HumanOmniExpressExome Bead chip (San Diego, CA, USA). For a subset of 
children, metabolomic profiling was performed by Metabolon, Inc. (NC, USA) on plasma 
samples (VDAART: ages 1 and 3; COPSAC2010: age 6 months) (supplementary methods). 
We extracted the five available metabolites from the sphingolipid biosynthesis pathway: 
sphingosine-1-phosphate (shown to be one of the most important sphingolipid metabolites 
for airway hyperresponsiveness, mast cell activation and inflammation in mechanistic 
asthma models [13, 14, 21]), sphinganine, sphinganine-1-phosphate, phosphoethanolamine 
and sphingosine.
Statistics
Differences between the vitamin D and placebo arms were assessed using the Chi-squared 
test. In each 17q21 genotype strata (GG, GC, CC), the effect of prenatal vitamin D 
supplementation on asthma/recurrent wheeze from age 0 to 3 years was analysed by event-
time models using Cox proportional hazards regression. Analyses were conducted 
independently in each cohort then combined using a fixed-effects meta-analysis model, 
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weighting estimates by the inverse of the estimate variance. The heterogeneity between the 
two studies was tested with a Cochran Q test and quantified using I2 statistics.
To explore the role of sphingolipid metabolism in the relationship between 17q21 genotype 
and asthma/recurrent wheeze, we determined the association between the vitamin D 
intervention and sphingolipid peak intensities at ages 1 and 3 years using linear regression 
models, stratified by 17q21 genotype. In order to account for the 203 subjects with measures 
of sphingolipids at both ages, we additionally performed combined analyses using a linear 
mixed model with a random intercept. We then constructed multivariable regression models 
to test for interactions between rs12936231 genotype, prenatal vitamin D supplementation 
and sphingolipid metabolite level in the risk of asthma/recurrent wheeze by age 3 years.
Assessment of sphingosine-1-phosphate concentration in an ORMDL3-overexpressing cell 
line
To determine whether there are functional implications of vitamin D treatment on 
sphingosine-1-phosphate levels when ORMDL3 is overexpressed, we used lentiviral-based 
infection to establish a human bronchial epithelial cell line, using 16HBE cells, that 
overexpressed ORMDL3. Supplementary figure E1 demonstrates the efficiency of the 
overexpression of ORMDL3, as demonstrated by both reverse transcriptase PCR at the 
mRNA level and by Western blotting at the protein level. We treated 16HBE cells with or 
without overexpression of ORMDL3 with 1α, 25-vitamin D3 (Sigma-Aldrich, St Louis, 
MO, USA) at varying concentrations (0.0, 0.1 and 1.0 nM) for 10 h, then measured 
cytoplasmic sphingosine-1-phosphate levels by ELISA (MyBioSource, San Diego, CA, 
USA). Three biological replicates were performed at each concentration. An unpaired t-test 
was used to compare induced sphingosine-1-phosphate levels (ng·mL−1) in the control cell 
line and in the cell line overexpressing ORMDL3 (supplementary methods).
All statistical analyses were conducted using R v.3.2.3 (R Foundation for Statistical 
Computing, Vienna, Austria) and the packages “survival”, “survminer”, “meta” and 
“AUCRF”. All hypothesis tests were two sided and a confidence level of 95% was 
employed.
Results
Baseline characteristics
The study populations for each of the conducted analyses are described in supplementary 
table E1. The primary analyses in both studies were based on those with genotype data and 
complete follow-up for asthma/recurrent wheeze until age 3 years (table 1). In VDAART, 
the genotype distribution was CC n=171 (27.7%), GC n=313 (50.6%) and GG n=134 
(21.7%), corresponding to a minor allele frequency (MAF) of 0.47 (G allele) and Hardy–
Weinberg equilibrium (HWE) p=0.72. In COPSAC2010, it was CC n=121 (23.4%), GC 
n=259 (50.1%) and GG n=137 (26.5%), corresponding to a MAF of 0.52 and HWE p=0.98. 
There was no difference in the distribution of genotype, sex, asthma/wheeze status or race 
between the vitamin D and placebo arms in either VDAART (vitamin D n=311, placebo 
n=307) or COPSAC2010 (vitamin D n=261, placebo n=256) and the relative proportions 
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were representative of the two parent studies [4, 5]. Serum vitamin D levels at age 3 years 
were available for VDAART only; although the point estimates were higher among the 
children whose mothers received the intervention, this difference was not significant. 
Similarly, there were no significant differences in serum vitamin D levels in VDAART 
between the placebo and intervention group when stratified by genotype (p>0.1 for all 
comparisons). In COPSAC2010 a proportion of mothers additionally received n-3 long-chain 
polyunsaturated fatty acids via fish-oil capsules during pregnancy, but we determined there 
was no significant difference in genotype distribution among the four intervention groups of 
vitamin D only, fish oil only, vitamin D and fish oil, and placebo only (supplementary table 
E2).
Vitamin D, 17q21 genotype and development of asthma/recurrent wheeze
The results from both trials suggested that the effect of the prenatal vitamin D 
supplementation on the development of asthma/recurrent wheeze from ages 0 to 3 years was 
dependent on the child’s 17q21 genotype, with an increasingly protective effect of vitamin D 
with decreasing number of C risk alleles (supplementary figure E2). The high-dose vitamin 
D intervention in the rs12936231 genotype strata in VDAART resulted in the following 
hazard ratios for developing asthma/recurrent wheeze: for CC, HR 1.07 (95% CI 0.59–1.95); 
for GC, HR 0.75 (95% CI 0.50–1.11); and for GG, HR 0.51 (95% CI 0.21–1.19). In 
COPSAC2010, the observed pattern was very similar: for CC, HR 1.08 (95% CI 0.55–2.15); 
for GC, HR 0.73 (95% CI 0.39–1.37); and for GG, HR 0.48 (95% CI 0.18–1.27).
A combined analysis of the two trials confirmed that the high-dose vitamin D intervention 
conferred a 50% reduced risk of developing asthma/recurrent wheeze by age 3 years in 
children with the low-risk GG genotype (fixed-effects HR 0.49, 95% CI 0.26–0.94). This 
protective effect decreased with increasing number of risk alleles (for GC, HR 0.74, 95% CI 
0.53–1.04; for CC, HR 1.08, 95% CI 0.69–1.69) (table 2). These findings also held true 
when assuming the G allele is dominant (supplementary table E3).
Vitamin D and sphingolipid metabolism
Metabolomic profiling of plasma was available in a subset of the VDAART children in the 
samples extracted at age 1 year (n=413) and age 3 years (n=353, including 203 of the 
children with a 1-year sample) (supplementary table E1). In the linear regression models, 
there was a consistently positive association between prenatal vitamin D intervention and 
higher levels of the five sphingolipids among children with the GG genotype. This 
association reached significance in the mixed models including all samples for 
sphinganine-1-phosphate (β 0.040, 95% CI 0.002–0.078, p=0.038) and sphingosine-1-
phosphate (β 0.022, 95% CI 0.001–0.044, p=0.038), and was approaching significance 
(p<0.1) for sphinganine, sphingosine and phosphoethanolamine. In contrast, there was no 
observed increase in sphingolipid levels associated with the vitamin D intervention in those 
children with the high-risk CC genotype (table 3). However, these findings were not 
recapitulated in the 6-month samples from 441 children from COPSAC2010 (supplementary 
table E4). Combined analyses with VDAART were not conducted owing to differences in 
sample collection age.
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Vitamin D, sphingolipid metabolism, 17q21 genotype and development of asthma/recurrent 
wheeze
In VDAART, sphingosine-1-phosphate, phosphoethanolamine and sphinganine-1-phosphate 
demonstrated a significant (p<0.05) or approaching significant (p<0.1) three-way interaction 
between the vitamin D intervention, rs12936231 genotype and metabolite peak intensity in 
the risk of asthma/recurrent wheeze at ages 1 and 3 years. This suggests that sphingolipid 
metabolites and the rs12936231 genotype may jointly influence the effect of vitamin D on 
asthma risk (supplementary table E5). However, significant interactions were not noted in 
the 6-month samples from COPSAC2010 (supplementary table E6).
Sensitivity analysis
Race—Sensitivity analyses were run to account for the potential influence of race in 
VDAART. Genotype frequencies were very similar in the African American (n=290 
children) and Caucasian (n=200) populations, although they deviated slightly in the “Other” 
category which included Asian and Native Hawaiian children (n=128) (supplementary table 
E7). Cox proportional regression models were rerun and stratified by race, and then the 
results were combined using a meta-analysis model. Owing to small numbers, the “Other” 
and “Caucasian” categories were combined. The combined results were supportive of the 
conclusion that the effect of prenatal vitamin D supplementation on the development of 
asthma/recurrent wheeze was modified by the 17q21 genotype (supplementary table E8). 
There was no protective effect of the vitamin D intervention in children with the high-risk 
CC genotype (HR 1.05, 95% CI 0.58–1.92), while there was a trend towards an increasingly 
protective effect with a decreasing number of risk alleles (for GC, HR 0.76, 95% CI 0.51–
1.14; for GG, HR 0.53, 95% CI 0.22–1.29). However, it should be noted that these results 
appeared to be largely driven by the data from African American children.
We additionally reran the regression models and interactions models for the sphingolipid 
analyses, stratifying by race category. While the overall pattern of results in terms of 
genotype and direction of effect held true across all populations for both the vitamin D 
supplementation–metabolite regression model (supplementary table E9) and the 
multivariable interaction model (supplementary table E10), there was some evidence that 
these results were being driven by data from children in the African American and Other 
populations.
Fish-oil supplementation—To reflect the fact that a proportion of the included mothers 
in COPSAC2010 were also receiving fish-oil supplementation throughout pregnancy, we 
reran the analyses excluding the 256 children of these women. When comparing the 128 
children whose mothers received only vitamin D with the 133 whose mothers received 
placebo only, there remained evidence of a trend for an increasing protective effect of 
vitamin D supplementation with decreasing number of C alleles. Furthermore, when 
combined with the VDAART population, the decreased risk in the GG strata was borderline 
significant with a similar magnitude to when the full COPSAC2010 population was included 
(HR 0.49, 95% CI 0.24–1.02, p=0.055), while there was no evidence of a protective effect in 
the CC strata (HR 1.00, 95% CI 0.60–1.66, p=0.999) (supplementary table E11).
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We reran the sphingolipid analyses excluding the children whose mothers had received fish-
oil supplementation throughout pregnancy. The results were largely unchanged for the 
regression models (supplementary table E12) in terms of direction of effect and significance 
level. Similarly, the results of the three-way interaction population were consistent when the 
fish-oil supplementation subgroup was removed (supplementary table E13). Taken together, 
these results suggest that concurrent fish-oil supplementation was not affecting the results in 
the COPSAC2010 population with regards to the genotype-specific protective effect of 
vitamin D supplementation and its relationship with sphingolipids.
Safety
There was no significant difference in the rates of severe adverse events between the trial 
arms in either study [4, 5].
Assessment of sphingosine-1-phosphate concentration in human bronchial epithelial cells
Given the observed interaction between vitamin D treatment, sphingosine-1-phosphate levels 
and the rs12936231 genotype in human subjects, we then explored the relationship between 
ORMDL3 expression and levels of sphingosine-1-phosphate in response to vitamin D 
treatment in cellular models. We performed three biological replicates at three 
concentrations of 1α, 25-vitamin D3: 0.0 nM, 0.1 nM and 1.0 nM. We then compared the 
mean level of induced sphingosine-1-phosphate (ng·mL−1) across the three replicates 
between the control and the ORMDL3-overexpressing cell line for each concentration. We 
found no significant difference in the levels of induced sphingosine-1-phosphate between the 
control and the ORMDL3-overexpressing cell line when treated with 0.0 nM and 0.1 nM of 
1α, 25-vitamin D3. However, there was a significant difference (p=0.002) between the 
control (mean of three replicates 62.3 ng·mL−1) and the ORMDL3 line (mean of three 
replicates 53.0 ng·mL−1) when treated with 1.0 nM (figure 1). This suggests that higher 
expression of ORMDL3, generally associated with risk CC genotype at rs12936231 [17], 
leads to reduced induction of sphingosine-1-phosphate by vitamin D in human bronchial 
epithelial cells.
Discussion
An increasing body of evidence now supports the preventive and protective potential of 
vitamin D on asthma and its symptoms [22]. This study suggests that the preventive actions 
of prenatal vitamin D supplementation on early childhood asthma/wheeze during the first 3 
years of life may be modified by genetic variants in 17q21, a crucial asthma genome-wide 
association study locus. Children with the low-risk GG genotype in rs12936231 whose 
mothers were supplemented with vitamin D had a 50% reduced risk of asthma, whereas 
there was no protective effect in children with the high-risk CC genotype. Based on our 
exploratory sphingolipid and functional work, we hypothesise that for a child with the non-
risk GG genotype, prenatal vitamin D supplementation increases sphingolipid metabolism, 
and subsequently the levels of downstream sphingolipids that are protective against asthma/
recurrent wheeze. Conversely, for a child with the high-risk CC genotype, increased 
expression of ORMDL3, known to inhibit a rate-limiting enzyme for de novo sphingolipid 
biosynthesis, SPT [23], modifies the relationship between vitamin D and sphingolipid 
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synthesis, and thus may render the vitamin D intervention ineffective at reducing asthma/
recurrent wheeze risk (figure 2).
17q21 was first discovered as a childhood asthma susceptibility locus in 2007, when genetic 
variants were shown to regulate transcription of the ORMDL3 gene in lymphoblastoid cell 
lines [24]. In this study we focused on a specific SNP in this region, rs12936231, a 
functional variant located in intron 4 of ZPBP2 that independently controls ORMDL3 
expression [12]. rs12936231 alters the CTCF binding motif with a G to C change, to the 
point where it is almost completely lost in the ZPBP2 intronic region for subjects carrying 
the asthma-risk C allele [12, 25]. Instead, it switches the binding site of CTCF to the 
ORMDL3 intronic region, which is hypothesised to alter the three-dimensional architecture 
of the 17q21 locus, favouring enhanced transcription of ORMDL3 [16, 12]. The asthma-
associated C allele of this SNP is therefore associated with downregulation of sphingolipid 
metabolism via increased expression of ORMDL3 and inhibition of SPT [25]. The link 
between sphingolipid metabolism and asthma is further supported by mouse studies showing 
that decreased sphingolipid synthesis in lung epithelial tissue [14] and SPT knockouts [21] 
both associate with increased airway hyperresponsiveness and inflammation [13], and that 
sphingolipids play an important role in the maturing postnatal lung [26]. Interestingly, 
experimental studies have shown that vitamin D metabolites are capable of activating the 
sphingolipid pathway [27, 28], and vitamin D has been shown to alter the recruitment of 
CTCF [18], making rs12936231 an SNP of particular interest for this study. rs12936231 is 
also unique in that it has been shown to impact the function of not only immune cells but 
also multiple other cell types that are potentially involved in asthma pathogenesis [16]. 
Taken together, it is biologically plausible that prenatal vitamin D supplementation acts to 
reduce the risk of childhood asthma in part through 17q21-dependent sphingolipid 
metabolism, and that rs12936231 is a particularly informative SNP to study in this regard.
We observed a clear allele-additive modifying effect, in two independent cohorts, of 
rs12936231, with a decreasing effect of the vitamin D intervention on asthma/recurrent 
wheeze with an increasing number of risk alleles. In VDAART, we then determined that 
prenatal vitamin D supplementation resulted in increased levels of key sphingolipids in 
offspring with the rs12936231 GG or GC genotype, but not those with the CC risk genotype. 
Furthermore, we present some evidence of significant interactions between prenatal vitamin 
D intervention with offspring genotype and sphingolipid metabolites on the risk of asthma/
recurrent wheeze, again suggesting that the effect of prenatal supplementation may be 
modified by these factors. Additional supporting evidence came from cellular models. 
Genetic overexpression of ORMDL3 led to decreased induction of sphingosine-1-phosphate 
in response to vitamin D treatment. This suggests that ORMDL3 may modify the vitamin 
D–sphingosine-1-phosphate relationship. Nevertheless, we recognise that no cellular model 
can completely recapitulate the effects of prenatal vitamin D supplementation on the risk of 
asthma in offspring. Furthermore, it should be noted that in addition to human bronchial 
epithelial cells there are other sources of sphingosine-1-phosphate production.
Differences in the trial design and populations between the two cohorts represent one of the 
biggest limitations of this study. VDAART is a high-risk cohort recruiting parents with 
asthma/allergy, and includes a large group of African Americans in the trial, who have a 
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higher risk of developing asthma and allergy [29]. In contrast, COPSAC2010 is a population-
based cohort which only genotyped Caucasian individuals. This is important because the 
17q21-associated increased risk of childhood asthma and 17q21 MAFs vary on an SNP-level 
basis across ethnicities [25]. However, we observed very similar MAFs in VDAART and 
COPSAC2010 and sensitivity analyses demonstrated that the genotype results were not 
confounded by race. Despite the heterogeneity between the trials, we observed a nearly 
identical pattern of an increasing preventive effect of vitamin D by decreasing number of 
17q21 risk alleles in both trials. It should also be noted that unlike VDAART, COPSAC2010 
had a randomisation within a cohort design; however, it has been stated that the findings 
from such studies are as valid as those from conventional RCT [30]; therefore, we are not 
concerned that this affected our results and conclusions regarding the influence of 
rs12936231.
We were not able to validate our exploratory sphingolipid findings from VDAART in the 
COPSAC2010 population, which we believe may be due to underlying differences between 
the populations. Potentially the most important of these differences was the factorial design 
of COPSAC2010, whereby a proportion of mothers were additionally receiving daily prenatal 
supplementation of n-3 long-chain polyunsaturated fatty acids via fish-oil capsules [31]. 
There is some evidence that fish oil can alter sphingolipid metabolism and sphingolipid 
levels [32, 33], which may explain the lack of difference in sphingolipid levels between the 
vitamin D and placebo groups. Therefore, we ran additional sensitivity analyses excluding 
the children of mothers who received fish oil throughout pregnancy. These analyses did not 
support our hypotheses that the lack of replication was due to the fish oil; however, we were 
somewhat limited by power in these analyses and we cannot discount that residual 
confounding from this additional supplementation may have influenced our COPSAC2010 
findings. Importantly, there were also substantial dietary differences between the two 
populations, with lower baseline levels of vitamin D and more vitamin D-deficient mothers 
in the VDAART trial [6], which likely resulted in differing baseline sphingolipid levels. 
Finally, the timing of the blood sampling, the onset of supplementation and the daily dose of 
vitamin D differed between the two cohorts, which may again explain the lack of replication.
Based on our race-stratified sphingolipid findings in the VDAART population, in which we 
found that the significant results of interest were primarily driven by the non-Caucasian 
children, we suggest that race may have played a role in our inability to replicate the 
sphingolipid findings in COPSAC2010. We are not aware of evidence in the literature for a 
difference in sphingolipid metabolism by race; however, there is evidence to suggest that 
vitamin D metabolism may differ by race [34], which may help to explain the results of our 
race-stratified analyses. Consequently, although the genetic findings were of similar 
magnitude and reached statistical significance when combined, and we demonstrated that the 
COPSAC2010 genetic findings were not driven by the fish-oil supplementation, further work 
is needed to explore the wider generalisability of the sphingolipid analyses.
We also note that we were limited by power in some of the cohort-specific stratified 
analyses, particularly with respect to the number of cases in the GG genotype strata. We note 
that for both cohorts the trend was the same, but it was only in the combined meta-analysis 
that the results reached significance. Furthermore, owing to the secondary and exploratory 
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nature of these analyses, they should be considered hypothesis generating and a nominal p-
value threshold was used to denote significance. Similarly, we did not account for multiple 
testing in our sphingolipid analysis; however, given the highly correlated nature of these 
metabolites and their existence within a single coordinated metabolic pathway, application 
of classical multiple testing corrections such as Bonferroni would be too stringent for such 
data. We also recognise that given the complexity of the 17q21 locus there are possibly other 
causal variants or genes that may influence risk. However, given the demonstrated 
independent functional nature of rs12936231 ORMDL3 expression [12, 16], and the role of 
ORMDL3 in sphingolipid biosynthesis [35], we consider these optimal for investigation.
Despite the limitations, this study was unique in our access to data from two independent 
prenatal vitamin D RCTs, which were aligned with respect to the predetermined endpoint of 
asthma/recurrent wheeze by age 3 years and having available genotyping. This enabled the 
discovery and replication of a 17q21 genotype-dependent effect of prenatal vitamin D 
intervention on asthma/recurrent wheeze. The sphingolipid data are a major advantage of 
this study and serve as an example of how this metabolomics, which provides a 
physiological “snapshot” of a biological system, may be useful for increasing the 
understanding of gene–environment interactions in health and disease. This approach 
enabled us to generate hypotheses regarding plausible underlying biological mechanisms 
[23], which we then explored in a cellular model.
We were unable to determine, within the confines of this study, whether the lack of 
preventive effect of vitamin D in children carrying the high-risk 17q21 genotype was due to 
our use of a dosage of vitamin D that was too low or was initiated too late in pregnancy or 
whether these children have a complete breakdown of the sphingolipid pathway rendering 
even high doses of vitamin D ineffective. We also recognise that vitamin D likely has other 
effects on fetal programming very early in pregnancy and may act to reduce the risk of 
asthma through immune modulations [36] and effects on lung organogenesis from branching 
morphogenesis throughout the alveolar stage of lung development [37, 38]. Furthermore, it 
has been previously noted that the effect of ORMLD3 overexpression on sphingolipid 
metabolism is dependent on both the extent of overexpression and the underlying 
physiological conditions [39]. Finally, we acknowledge that race may have influenced our 
findings, particularly with regard to the sphingolipid results. Additional work is required to 
explore these issues, specifically within a study with adequate sample size and power for the 
strata of interest.
Conclusion
This is the first study to demonstrate a link between vitamin D and the 17q21 locus in the 
development of childhood asthma and recurrent wheeze. Based on our exploratory analyses, 
we suggest that vitamin D acts to reduce the risk of asthma through an increase in 
sphingolipid metabolism, but that this pathway may be attenuated in those with key genetic 
variants in 17q21 that influence the expression of ORMDL3. These findings provide 
additional insights into the pathogenesis of childhood asthma and in particular the role of 
ORMDL3-regulated sphingolipid pathways [15].
Kelly et al. Page 10
Eur Respir J. Author manuscript; available in PMC 2020 April 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements:
The authors wish to thank the study participants of the VDAART and COPSAC2010 trials and all those involved in 
collecting and managing the data for the parent studies. The results of the primary trials and a combined analysis of 
the two trials have been published previously.
Support statement: VDAART was supported by U01HL091528, 1R01HL123915-01 and 1R01HL123546-01A1 
from the National Heart, Lung, and Blood Institute (NHLBI); and U54TR001012 from the National Centers for 
Advancing Translational Sciences. Metabolomic analyses and R.S. Kelly were supported by 5R01HL123915-05, 
1R01HL141826-0 and W81XWH-17-1-0533. COPSAC2010 was supported by The Lundbeck Foundation (R16-
A1694); The Danish Ministry of Health (903516); Danish Council for Strategic Research (grant number 
0603-00280B) and The Capital Region Research Foundation (full list www.copsac.com). B.L. Chawes was 
supported by a European Respiratory Society fellowship. The funding bodies played no role in the design or 
conduct of the study; collection, management, analysis or interpretation of the data; preparation, review or approval 
of the manuscript; nor decision to submit the manuscript for publication. Funding information for this article has 
been deposited with the Crossref Funder Registry.
References
1. Bouzigon E, Corda E, Aschard H, et al. Effect of 17q21 variants and smoking exposure in early-
onset asthma. N Engl J Med 2008; 359: 1985–1994. [PubMed: 18923164] 
2. Çalışkan M, Bochkov YA, Kreiner-Møller E, et al. Rhinovirus wheezing illness and genetic risk of 
childhood-onset asthma. N Engl J Med 2013; 368: 1398–1407. [PubMed: 23534543] 
3. Renz H, Conrad M, Brand S, et al. Allergic diseases, gene–environment interactions. Allergy 2011; 
66: 10–12. [PubMed: 21668842] 
4. Litonjua AA, Carey VJ, Laranjo N, et al. Effect of prenatal supplementation with vitamin D on 
asthma or recurrent wheezing in offspring by age 3 years: The VDAART randomized clinical trial. 
JAMA 2016; 315: 362–370. [PubMed: 26813209] 
5. Chawes BL, Bønnelykke K, Stokholm J, et al. Effect of vitamin D3 supplementation during 
pregnancy on risk of persistent wheeze in the offspring: a randomized clinical trial. JAMA 2016; 
315: 353–361. [PubMed: 26813208] 
6. Wolsk HM, Chawes BL, Litonjua AA, et al. Prenatal vitamin D supplementation reduces risk of 
asthma/recurrent wheeze in early childhood: a combined analysis of two randomized controlled 
trials. PLoS One 2017; 12: e0186657. [PubMed: 29077711] 
7. Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association 
study of asthma. N Engl J Med 2010; 363: 1211–1221. [PubMed: 20860503] 
8. Torgerson DG, Ampleford EJ, Chiu GY, et al. Meta-analysis of genome-wide association studies of 
asthma in ethnically diverse North American populations. Nat Genet 2011; 43: 887–892. [PubMed: 
21804549] 
9. Bisgaard H, Bonnelykke K, Sleiman PM, et al. Chromosome 17q21 gene variants are associated 
with asthma and exacerbations but not atopy in early childhood. Am J Respir Crit Care Med 2009; 
179: 179–185. [PubMed: 19029000] 
10. Stokholm J, Chawes BL, Vissing N, et al. Cat exposure in early life decreases asthma risk from the 
17q21 high-risk variant. J Allergy Clin Immunol 2018; 141: 1598–1606. [PubMed: 29102067] 
11. Hanada K Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim 
Biophys Acta 2003; 1632: 16–30. [PubMed: 12782147] 
12. Verlaan DJ, Berlivet S, Hunninghake GM, et al. Allele-specific chromatin remodeling in the 
ZPBP2/GSDMB/ORMDL3 locus associated with the risk of asthma and autoimmune disease. Am 
J Hum Genet 2009; 85: 377–393. [PubMed: 19732864] 
13. Ono JG, Worgall TS, Worgall S. Airway reactivity and sphingolipids—implications for childhood 
asthma. Mol Cell Pediatr 2015; 2: 1–6. [PubMed: 26542291] 
Kelly et al. Page 11
Eur Respir J. Author manuscript; available in PMC 2020 April 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
14. Worgall TS, Veerappan A, Sung B, et al. Impaired sphingolipid synthesis in the respiratory tract 
induces airway hyperreactivity. Sci Transl Med 2013; 5: 186ra167.
15. Miller M, Broide DH. Why is ORMDL3 on chromosome 17q21 highly linked to asthma? Am J 
Respir Crit Care Med 2019; 199: 404–406. [PubMed: 30365391] 
16. Schmiedel BJ, Seumois G, Samaniego-Castruita D, et al. 17q21 asthma-risk variants switch CTCF 
binding and regulate IL-2 production by T cells. Nat Commun 2016; 7: 13426. [PubMed: 
27848966] 
17. Sharma S, Zhou X, Thibault DM, et al. A genome-wide survey of CD4(+) lymphocyte regulatory 
genetic variants identifies novel asthma genes. J Allergy Clin Immunol 2014; 134: 1153–1162. 
[PubMed: 24934276] 
18. Seuter S, Neme A, Carlberg C. Characterization of genomic vitamin D receptor binding sites 
through chromatin looping and opening. PLoS One 2014; 9: e96184. [PubMed: 24763502] 
19. Litonjua AA, Lange NE, Carey VJ, et al. The Vitamin D Antenatal Asthma Reduction Trial 
(VDAART): rationale, design, and methods of a randomized, controlled trial of vitamin D 
supplementation in pregnancy for the primary prevention of asthma and allergies in children. 
Contemp Clin Trials 2014; 38: 37–50. [PubMed: 24614387] 
20. Bisgaard H The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): design, 
rationale, and baseline data from a longitudinal birth cohort study. Ann Allergy Asthma Immunol 
2004; 93: 381–389. [PubMed: 15521375] 
21. Miller M, Rosenthal P, Beppu A, et al. ORMDL3 transgenic mice have increased airway 
remodeling and airway responsiveness characteristic of asthma. J Immunol 2014; 192: 3475–3487. 
[PubMed: 24623133] 
22. Martineau AR, Cates CJ, Urashima M, et al. Vitamin D for the management of asthma. Cochrane 
Database Syst Rev 2016; 9: CD011511. [PubMed: 27595415] 
23. Breslow DK, Collins SR, Bodenmiller B, et al. Orm family proteins mediate sphingolipid 
homeostasis. Nature 2010; 463: 1048–1053. [PubMed: 20182505] 
24. Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression 
contribute to the risk of childhood asthma. Nature 2007; 448: 470–473. [PubMed: 17611496] 
25. Stein MM, Thompson EE, Schoettler N, et al. A decade of research on the 17q12–21 asthma locus: 
piecing together the puzzle. J Allergy Clin Immunol 2018; 142: 749–764. [PubMed: 29307657] 
26. Dautel SE, Kyle JE, Clair G, et al. Lipidomics reveals dramatic lipid compositional changes in the 
maturing postnatal lung. Sci Rep 2017; 7: 40555. [PubMed: 28145528] 
27. Magrassi L, Adorni L, Montorfano G, et al. Vitamin D metabolites activate the sphingomyelin 
pathway and induce death of glioblastoma cells. Acta Neurochir 1998; 140: 707–714. [PubMed: 
9781285] 
28. Manggau M, Kim D-S, Ruwisch L, et al. 1α,25-Dihydroxyvitamin D3 protects human 
keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol 
2001; 117: 1241–1249. [PubMed: 11710939] 
29. Lester LA, Rich SS, Blumenthal MN, et al. Ethnic differences in asthma and associated 
phenotypes: Collaborative Study on the Genetics of Asthma. J Allergy Clin Immunol; 108: 357–
362. [PubMed: 11544453] 
30. van der Velden JM, Verkooijen HM, Young-Afat DA, et al. The cohort multiple randomized 
controlled trial design: a valid and efficient alternative to pragmatic trials? Int J Epidemiol 2017; 
46: 96–102. [PubMed: 27118559] 
31. Bisgaard H, Stokholm J, Chawes BL, et al. Fish oil-derived fatty acids in pregnancy and wheeze 
and asthma in offspring. N Engl J Med 2016; 375: 2530–2539. [PubMed: 28029926] 
32. Vesper H, Schmelz E-M, Nikolova-Karakashian MN, et al. Sphingolipids in food and the emerging 
importance of sphingolipids to nutrition. J Nutr 1999; 129: 1239–1250. [PubMed: 10395583] 
33. Babenko NA. Brain, fish oil-enriched diet, and sphingolipids In: Raatz SK, Bibus DM, eds. Fish 
and Fish Oil in Health and Disease Prevention. San Diego, Academic Press, 2016; pp. 263–272.
34. Haddad SA, Ruiz-Narvaez EA, Cozier YC, et al. Association of degree of European genetic 
ancestry with serum vitamin D levels in African Americans. Am J Epidemiol 2018; 187: 1420–
1423. [PubMed: 29390092] 
Kelly et al. Page 12
Eur Respir J. Author manuscript; available in PMC 2020 April 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
35. Worgall TS. Sphingolipids, ORMDL3 and asthma: what is the evidence? Curr Opin Clin Nutr 
Metab Care 2017; 20: 99–103. [PubMed: 28030368] 
36. Hollams EM, Hart PH, Holt BJ, et al. Vitamin D and atopy and asthma phenotypes in children: a 
longitudinal cohort study. Eur Respir J 2011; 38: 1320–1327. [PubMed: 21565922] 
37. Kho AT, Sharma S, Qiu W, et al. Vitamin D related genes in lung development and asthma 
pathogenesis. BMC Med Genomics 2013; 6: 47. [PubMed: 24188128] 
38. Zosky GR, Berry LJ, Elliot JG, et al. Vitamin D deficiency causes deficits in lung function and 
alters lung structure. Am J Respir Crit Care Med 2011; 183: 1336–1343. [PubMed: 21297070] 
39. Oyeniran C, Sturgill JL, Hait NC, et al. Aberrant ORM (yeast)-like protein isoform 3 (ORMDL3) 
expression dysregulates ceramide homeostasis in cells and ceramide exacerbates allergic asthma in 
mice. J Allergy Clin Immunol 2015; 136: 1035–1046.e1036. [PubMed: 25842287] 
Kelly et al. Page 13
Eur Respir J. Author manuscript; available in PMC 2020 April 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIGURE 1. 
Measurements of sphingosine-1-phosphate (S1P) levels in 16HBE cells after vitamin D3 
treatment. 16HBE human bronchial epithelial cells and ORMDL3-overexpressing stable 
16HBE cells were treated with vitamin D3 at three concentrations (0.0, 0.1 and 1.0 nM) for 
10 h. Levels of S1P in cells were measured by ELISA. Mean±SD shown for three 
independent experiments in ELISA assay. *: p<0.05, unpaired t-test.
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FIGURE 2. 
Hypothesised mechanism. a) Sphingolipid metabolism: serine palmitoyltransferase catalyses 
a crucial reaction in the production of sphingolipids. ORMDL3 inhibits the action of serine 
palmitoyltransferase and therefore the de novo pathway production of sphingolipids. 
Expression of ORMDL3 is increased by the CC genotype at rs12936231, leading to 
increased inhibition of sphingolipid production. b) Hypothesised mechanism: prenatal 
vitamin D supplementation increases the production of sphingolipids in offspring via the 
sphingolipid metabolism pathway, resulting in a decreased risk of asthma. When ORMDL3 
is overexpressed the sphingolipid metabolism pathway is inhibited, sphingolipid production 
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is not increased and there is no protective effect of vitamin D on asthma risk. CoA: 
coenzyme A.
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TABLE 1
Baseline characteristics of the participants from the VDAART and COPSAC2010 prenatal vitamin D trials with 
genotype data stratified by intervention
Characteristic VDAART# COPSAC2010
¶
Placebo Vitamin D p-value Placebo Vitamin D p-value
Subjects n 307 311 256 261
rs12936231
 CC 78 (25.4) 93 (29.9) 0.454 59 (23) 62 (23.8) 0.820
 GC 161 (52.4) 152 (48.9) 126 (49.2) 133 (51)
 GG 68 (22.1) 66 (21.2) 71 (27.7) 66 (25.3)
Asthma/wheeze, 0–3 years
 No 215 (70) 235 (75.6) 0.146 206 (80.5) 219 (83.9) 0.364
 Yes 92 (30) 76 (24.4) 50 (19.5) 42 (16.1)
Sex
 Male 164 (53.4) 157 (50.5) 0.515 128 (50) 141 (54) 0.408
 Female 143 (46.6) 154 (49.5) 128 (50) 120 (46)
Race
 Black 146 (47.6) 144 (46.3) 0.359
 Caucasian 92 (30) 108 (34.7) 256 (100) 256 (100)
 Other 69 (22.5) 59 (19)
Serum vitamin D at age 3 years+ ng·mL−1 20.71±8.19 21.16±9.32 0.630
Data are presented as n (%) or mean±SD, unless otherwise indicated. VDAART: Vitamin D Antenatal Asthma Reduction Trial; COPSAC2010: 
Copenhagen Prospective Studies on Asthma in Childhood 2010.
#:
the total VDAART population was 806 children, data for 618 were included, the dose was 4400 IU daily in the intervention arm versus 400 IU in 
the placebo arm and was initiated in weeks 10–18;
¶:
the total COPSAC2010 population was 581, data for 517 were included, the dose was 2800 IU daily in the intervention arm versus 400 IU in the 
placebo arm and was initiated in weeks 22–26;
+:
available for VDAART only.
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TABLE 2
Effect of prenatal vitamin D supplementation versus placebo on the development of asthma/persistent wheeze 
from 0 to 3 years in the VDAART and COPSAC2010 trials stratified by genotype of the 17q21 functional SNP 
rs12936231
rs12936231 
strata VDAART
# COPSAC2010
¶ Combined analyses
Total/cases n HR (95% CI) p-value Total/cases 
n
HR (95% CI) p-value HR+ (95% CI) p-value
GG 134/23 0.51 (0.21–1.19) 0.119 137/19 0.48 (0.18–1.27) 0.140 0.49 (0.26–0.94) 0.032
GC 313/101 0.75 (0.50–1.11) 0.147 259/40 0.73 (0.39–1.37) 0.327 0.74 (0.53–1.04) 0.080
CC 171/44 1.07 (0.59–1.95) 0.821 121/33 1.08 (0.55–2.15) 0.822 1.08 (0.69–1.69) 0.751
Cases refer to the number of children with asthma/persistent wheeze at from age 0 to 3 years. VDAART: Vitamin D Antenatal Asthma Reduction 
Trial; COPSAC2010: Copenhagen Prospective Studies on Asthma in Childhood 2010; SNP: single nucleotide polymorphism.
#:
n=618;
¶:
n=517;
+ :fixed-effects meta-analysis HR combining VDAART and COPSAC2010.
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TABLE 3
Association between blood peak intensity of five key sphingolipid metabolites and vitamin D intervention in 
VDAART children stratified by 17q21 genotype
Age 1 year# Age 3 years¶ All samples+
Coefficient (95% CI) p-value Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Sphinganine-1-phosphate
 CC −0.016 (−0.073–0.002) 0.065 0.001 (−0.044–0.051) 0.895 −0.015 (−0.048–0.017) 0.350
 GC 0.003 (−0.019–0.034) 0.580 0.004 (−0.026–0.043) 0.635 0.007 (−0.016–0.029) 0.548
 GG 0.016 (−0.013–0.086) 0.147 0.017 (−0.014–0.094) 0.149 0.040 (0.002–0.078) 0.038§
Sphinganine
 CC −0.004 (−0.072–0.052) 0.752 0.006 (−0.067–0.094) 0.744 0.001 (−0.052–0.053) 0.982
 GC 0.010 (−0.023–0.067) 0.334 −0.007 (−0.073–0.043) 0.608 0.005 (0.032–0.042) 0.787
 GG 0.013 (−0.079–0.141) 0.586 0.041 (−0.002–0.193) 0.059 0.065 (−0.011–0.141) 0.091
Sphingosine-1-phosphate
 CC −0.009 (−0.039–0) 0.054 −0.001 (−0.032–0.027) 0.872 −0.012 (−0.031–0.007) 0.212
 GC −4.6E-04 (−0.017–0.015) 0.898 0.003 (−0.016–0.028) 0.610 0.002 (−0.012–0.016) 0.776
 GG 0.006 (−0.015–0.042) 0.352 0.015 (0.005–0.065) 0.027§ 0.022 (0.001–0.044) 0.038§
Sphingosine
 CC −0.009 (−0.077–0.037) 0.486 0.005 (−0.059–0.084) 0.733 −0.005 (−0.052–0.041) 0.821
 GC 0.010 (−0.019–0.065) 0.284 −0.006 (−0.07–0.04) 0.599 0.006 (−0.029–0.041) 0.736
 GG 0.009 (−0.077–0.118) 0.679 0.043 (0.015–0.185) 0.024§ 0.057 (−0.01–0.124) 0.094
Phosphoethanolamine
 CC −0.009 (−0.069–0.027) 0.389 0.015 (−0.006–0.074) 0.096 0.003 (−0.032–0.038) 0.870
 GC −0.011 (−0.06–0.008) 0.142 −0.009 (−0.054–0.014) 0.251 −0.021 (−0.047–0.005) 0.120
 GG 0.020 (−0.016–0.108) 0.152 0.018 (−0.005–0.086) 0.086 0.038 (−0.003–0.08) 0.071
VDAART: Vitamin D Antenatal Asthma Reduction Trial.
#:CC n=112 (27%), GC n=221 (54%), GG n=80 (19%);
¶:CC n=106 (30%), GC n=172 (49%), GG n=75 (21%);
+:
all samples combined according to a mixed model, CC n=218 (28%), GC n=393 (51%), GG n=155 (20%);
§:
significant at the 95% confidence interval.
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